Hadassah

Collaboration Announced to Develop Hadassah Drug to Treat “Untreatable” NASH Liver Disease

Friday, Aug 5 2016

Hadasit, the Hadassah Medical Organization’s technology transfer company, has signed an agreement with BioLineRx Ltd. to develop a drug to treat non-alcoholic steatohepatitis (NASH), based on the pre-clinical work of Hadassah’s Prof. Rifaat Safadi, head of its Liver Unit. Currently, there are no Federal Drug Administration-approved treatments for NASH.

NASH is the progressive form of non-alcoholic fatty liver disease (NAFLD) and, in many cases, leads to cirrhosis of the liver and, ultimately, liver cancer. This “in-licensing agreement” represents a partnership between two companies with shared intentions, goals, and fields of interest. "Under the collaboration,” explains Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx,” Novartis will provide us with valuable professional advice and consultancy throughout the development process. This project fits our strategic focus on the immunology space, since it works through modulation of the immune system.”

The drug candidate, to be called BL-1210, offers a novel mechanism for controlling liver fibrosis, the scarring process that represents the liver's response to injury. When scar tissue builds up and takes over most of the liver, cirrhosis is the result. By modulating the immune system, the drug would reduce scarring and control the disease’s progression.

As Hadasit explains about the Hadassah Medical Center on its website, “The combination of practical experience, the ability to pinpoint medical needs, and cutting-edge research has yielded a huge potential for ideas, innovation, and developments in all aspects of medicine, including therapeutics, diagnostics, and medical devices. Founded in 1986, Hadasit has been investing in turning ideas into viable products and services for the benefit of humanity.”

Comments

From: Michelle on August 25, 2016
I was first diagnosed with NASH in 2003. Nobody I knew had ever heard of NASH. At the beginning even some of my doctors, often were unknowldgeable on NASH. I was their key to unlock the information vault. I am willing to be a test subject.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Aug 17 2018

Hadassah Mourns the Loss of Aretha Franklin and Urges Greater Awareness of Diagnosis and Treatment of Pancreatic Cancer

Sadly, the “queen of soul” Aretha Franklin passed away yesterday at age 76, due to an advanced pancreatic neuroendocrine tumor (pancreatic NET or PNET).

READ MORE ›
alt_text

Wednesday, Aug 15 2018

Hadassah Hospital’s Bone Marrow Transplant Department Receives International Acclaim

In a first for Israel, Hadassah Medical Organization’s Bone Marrow Transplantation and Cancer Immunotherapy Department has recently received full accreditation by the Joint Accreditation Committee ISCT-EUROPE & EBMT (JACIE), Europe’s only official accreditation body in the field.

READ MORE ›
alt_text

Tuesday, Aug 14 2018

Hadassah Hospital Helps Educate Mikvah Attendants To Bolster Women’s Health

After a woman emerges from the ritual bath (mikveh) and wraps herself in a towel, says mikveh attendant Daniella Salomon, “I keep an eye out” for anything unusual.

READ MORE ›
alt_text

Tuesday, Aug 7 2018

American Medical Attaché and Consulate Nurse Tour Hadassah Hospital Ein Kerem

Jennifer Kmiecinski, Medical Attaché to the Consulate General of the United States in Israel, visited Hadassah Hospital Ein Kerem earlier this month to assess the level of health care available to American personnel serving in Israel.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More